Elotuzumab Combination Therapy

PRIMARY OBJECTIVE:

I. To evaluate the safety and tolerability of elotuzumab, mezigdomide (CC-92480), and dexamethasone (E480d) in patients with relapsed/refractory multiple myeloma (RRMM) who have received >= 2 prior regimens including CD38- and BCMA-targeted therapies.

SECONDARY OBJECTIVES:

I. To evaluate the objective response rate (ORR) (per International Myeloma Working Group [IMWG] criteria) of E480d.

II. Determine the time to response (TTR), the duration of response (DOR), progression free survival (PFS) at 1 year, and overall survival (OS) at 1 year.

III. Check minimal residual disease (MRD) negativity rates by next generation sequencing in patients who are suspected of attaining a complete response (CR).

IV. Correlative studies will include changes in lymphocyte subsets with therapy, immunophenotype of MM cells, and expression of CRBN, Ikaros, and Aiolos.

V. Quality of life (QOL) will be assessed.

OUTLINE: This is a dose-escalation study of CC-92480, followed by a dose-expansion study.

Patients receive elotuzumab intravenously (IV) on days 1, 8, 15, and 22 of cycles 1 and 2 and then on day 1 of each subsequent cycle. Patients also receive CC-92480 orally (PO) on days 1-21 of each cycle and dexamethasone IV or PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo an echocardiography (ECHO) during screening and undergo magnetic resonance imaging (MRI), computed tomography (CT), or x-ray imaging during screening and on study as clinically indicated. Patients also undergo blood sample collection as well as bone marrow biopsy and aspiration during screening and on study.

After completion of study treatment, patients are followed up at 30 and 60 days and then every 12 weeks for up to 2 years.